The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in chinese subjects: A randomized, placebo-controlled study

American Journal of Clinical Dermatology

Volumn 14, Issue 2, 2013, Pages 147-153

  Wang, Yuan ^a   Wang, Mei ^a   Xiao, Shengxiang ^a   Pan, Ping ^a   Li, Ping ^a   Huo, Jia ^a  

^a THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIRELINE; HEXAPEPTIDE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHINESE; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORBIT; PARALLEL DESIGN; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WRINKLE;

ADMINISTRATION, TOPICAL; ADULT; CHINA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ESTHETICS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PATIENT SATISFACTION; PROSPECTIVE STUDIES; SKIN AGING; TREATMENT OUTCOME;

EID: 84879512054     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-013-0009-9     Document Type: Article

References (22)

1. Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20:343-9.
2. Lupo MP. Cosmeceutical peptides. Dermatol Surg. 2005;31:832-6.
3. Gutierrez LM, Cannes JM, Ferrer-Monteil AV, et al. A peptide that mimics the carboxy-terminal domain of SNAP-25 blocks Ca2+-dependent exocytosis in chromaffin cells. FEBS Lett. 1995;372:39-43.
4. Gutierrez LM, Viniegra S, Reuda J, et al. A peptide that mimics the C-terminal sequence of SNAP-25 inhibits secretory vesicle docking in chromaffin cells. J Biol Chem. 1997;272:2634-9.
5. Blanes-Mira C, Clementey J, Jodas G, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24:303-10.
6. Yamauchi P, Lowe N. Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhidrosis. Clin Dermatol. 2004;22:34-9.
7. Vartanian AJ, Dayan SH. Facial rejuvenation using botulinum toxin A: a review and updates. Facial Plast Surg. 2004;20:11-9.
8. Daniell HW. Smoker's wrinkles: a study in the epidemiology of "crow's feet". Ann Intern Med. 1971;75(6):873-80.
9. Seeman D, Alster TS. Combination radiofrequency and diode laser for treatment of facial rhytides and skin laxity. Cosmet Laser Ther. 2005;7:11-5.
10. Carruthers JDA, Carruthers JA. Treatment of glabellar frown lines with C botulinum A exotoxin. J Dermatol Surg Oncol. 1992;18:17-21.
11. Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46:840-9.
12. Harii K, Kawashima M. A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plast Surg. 2008;32:724-30.
13. Fagien S, Cox SE, Finn JC, et al. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatol Surg. 2007;33(1 Spec No.):S2-9.
14. Carruthers A, Carruthers J. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg. 2005;31:1297-303.
15. Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg. 2005;31:414-22 (discussion 422).
16. Carruthers JD, Lowe NJ, BoNTA Glabellar Lines II Study Group, et al. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg. 2003;112:1089-98.
17. American Society for Aesthetic Plastic Surgery. 11.5 million cosmetic procedures in 2006. 2007 [online]. Available from URL: http://www.surgery.org/ press/news-release.php?iid=465 [Accessed 2008 Jul 28].
18. Benedetto AV. The cosmetic use of botulinum neurotoxin type A. Int J Dermatol. 1999;38:641-55.
19. Becker-Wegerich PM, Rauch L, Ruzicka T. Botulinum toxin: a successful decollete rejuvenation. Dermatol Surg. 2002;28:168-71.
20. Frankel AS. Botox for rejuvenation of the periorbital region. Facial Plast Surg. 1999;15:255-62.
21. Johnson EA. Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu Rev Microbiol. 1999;53:551-75.
22. Chen YA, Scheller RH. SNARE-mediated membrane fusion. Nat Rev Mol Cell Biol. 2001;2:98-106.